DRR168517
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.480
- IL6_JAK_STAT3_SIGNALING+0.380
- CHOLESTEROL_HOMEOSTASIS+0.340
- INFLAMMATORY_RESPONSE+0.330
- BILE_ACID_METABOLISM+0.320
- KRAS_SIGNALING_UP+0.280
- PROTEIN_SECRETION+0.260
- XENOBIOTIC_METABOLISM+0.240
- ALLOGRAFT_REJECTION+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.470
- NOTCH_SIGNALING-0.460
- OXIDATIVE_PHOSPHORYLATION-0.410
- E2F_TARGETS-0.380
- DNA_REPAIR-0.350
- G2M_CHECKPOINT-0.330
- MITOTIC_SPINDLE-0.330
- APICAL_JUNCTION-0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303769 | — | — | 0.810 |
| 2 | TCGA-F7-A50G-01A-11R-A266-07 | — | — | 0.803 |
| 3 | SRR601169 | GTEX | — | 0.802 |
| 4 | SRR25043624 | — | — | 0.801 |
| 5 | SRR12475112 | — | — | 0.798 |
| 6 | SRR1362777 | GTEX | — | 0.798 |
| 7 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.797 |
| 8 | SRR12475115 | — | — | 0.789 |
| 9 | 3a2b80a5-6937-423a-92bf-9e25a0b23c5b | — | — | 0.782 |
| 10 | SRR1323603 | GTEX | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |